Glucophage is used to help adults manage blood glucose in Type 2 diabetes. Its active ingredient, metformin hydrochloride, reduces excess glucose production by the liver and improves the body’s…
Glucophage is used to help adults manage blood glucose in Type 2 diabetes. Its active ingredient, metformin hydrochloride, reduces excess glucose production by the liver and improves the body’s response to insulin. It is taken as oral tablets alongside an appropriate eating plan and physical activity.
Glucophage contains metformin hydrochloride, an oral antidiabetic medicine from the biguanide class. It is used mainly for Type 2 diabetes, also called non-insulin-dependent diabetes, when the body still produces insulin but does not use it efficiently or cannot produce enough to maintain healthy blood glucose.
Metformin is not an insulin replacement. It works by reducing unnecessary glucose release from the liver and helping muscle cells respond more effectively to insulin. This action can improve fasting and after-meal blood glucose without directly forcing the pancreas to release large amounts of insulin [1].
Metformin hydrochloride is the pharmaceutical form of metformin used in Glucophage tablets. It has a low risk of causing hypoglycaemia when taken alone because it does not usually stimulate insulin secretion independently of the body’s glucose level.
The medicine may be used alone or alongside other diabetes treatments. The appropriate dose is decided individually, taking age, other medicines, kidney function, and additional health conditions into account.
Glucophage is intended for adults with Type 2 diabetes who need improved blood glucose regulation. It is often useful in people with insulin resistance and may be suitable for patients who are overweight, especially when avoiding treatment-related weight gain is clinically desirable.
Body weight alone does not determine suitability. A person with a healthy weight can have insulin-resistant Type 2 diabetes, while an overweight person may require another treatment because of kidney impairment, severe illness, or another contraindication.
Glucophage contains metformin hydrochloride, an oral antidiabetic medicine from the biguanide class. It is used mainly for Type 2 diabetes, also called non-insulin-dependent diabetes, when the body still produces insulin but does not use it efficiently or cannot produce enough to maintain healthy blood glucose.
Metformin hydrochloride is the pharmaceutical form of metformin used in Glucophage tablets. It has a low risk of causing hypoglycaemia when taken alone because it does not usually stimulate insulin secretion independently of the body’s glucose level.
The medicine may be used alone or alongside other diabetes treatments. The appropriate dose is decided individually, taking age, other medicines, kidney function, and additional health conditions into account.
Glucophage contains metformin, which reduces unnecessary glucose release from the liver. It also helps muscle cells respond more effectively to insulin, improving the movement and use of glucose without directly forcing the pancreas to release large amounts of insulin.
Glucophage is taken by mouth as tablets. The dose is decided individually, taking age, other medicines and health conditions into account.
The product data identifies the dosage form as tablets. Immediate-release and extended-release metformin have different instructions, so a tablet should not be crushed, split, or chewed unless the prescribed formulation allows it.
Extended-release metformin uses a formulation that releases the active substance more gradually through the digestive tract. The slower release can reduce the intensity of gastrointestinal symptoms for some people and may make the dosing schedule easier to follow.
This does not make extended-release tablets suitable for everyone. The release characteristics depend on the formulation, so a tablet must not be crushed or chewed unless the prescribed product specifically permits it.
Gastrointestinal effects can still occur. Loose stools, abdominal discomfort, nausea, and reduced appetite remain possible. Changing from one formulation to another should follow an individual dosing plan rather than an automatic tablet-for-tablet substitution.
Glucophage belongs to a different treatment group from medicines that increase insulin release or replace insulin directly.
| Treatment approach | Main glucose effect | Practical limitation |
|---|---|---|
| Metformin | Reduces liver glucose production and improves insulin sensitivity | Gastrointestinal symptoms may occur |
| Insulin therapy | Replaces or supplements insulin directly | Hypoglycaemia and weight gain can occur |
| Insulin-secretagogue therapy | Encourages the pancreas to release more insulin | Hypoglycaemia and weight gain may be more likely |
Metformin is often selected when insulin resistance contributes substantially to Type 2 diabetes. It is also useful when avoiding treatment-related weight gain is a priority. Insulin may be preferred when the pancreas produces very little insulin, glucose levels are severely elevated, or pregnancy-specific treatment goals require it.
The choice depends on kidney function, cardiovascular or liver disease, HbA1c, age, eating patterns, concurrent medicines, and the person’s ability to recognise and manage low blood glucose.
Several practical errors can make Glucophage seem less tolerable or less effective:
Glucophage is not suitable for everyone. The medicine requires careful assessment in the following situations:
Metformin may need temporary interruption around iodinated contrast procedures or major surgery. The decision depends on kidney function and the type of procedure.
Some medicines can affect the safety of metformin by altering renal function, hydration, or glucose control. These include certain diuretics, medicines that affect blood pressure or kidney blood flow, systemic corticosteroids, and other glucose-lowering medicines. Alcohol can increase the risk of lactic acidosis, especially when intake is heavy or food consumption is poor.
It may not be for you if you have severe kidney impairment, previous lactic acidosis, or another contraindication identified by a clinician. Before treatment begins, clinicians assess kidney function, current glucose control, alcohol intake, liver and heart conditions, and medicines that may affect renal function or hydration. Metformin is removed through the kidneys, so reduced renal clearance can raise the risk of accumulation and lactic acidosis, a rare but serious metabolic complication [2].
Pregnancy and breastfeeding require an individual treatment decision. Existing diabetes during pregnancy needs close glucose monitoring because both high and low glucose can affect maternal and fetal health.
Digestive symptoms are the most common unwanted effects during the first days or weeks of metformin treatment. They often become less troublesome when the dose is increased gradually and taken with food.
Possible effects include:
These symptoms are usually related to the gastrointestinal tract rather than an allergy. Severe or persistent diarrhoea can cause dehydration and may affect kidney function.
Long-term metformin use can reduce vitamin B12 absorption in some patients. Symptoms such as unusual tiredness, sore tongue, numbness, pins and needles, balance problems, or pale skin can justify a B12 assessment.
Lactic acidosis is rare but serious. Warning symptoms can include profound weakness, unusual sleepiness, breathing difficulty, persistent vomiting, abdominal pain, feeling cold, slow heartbeat, or marked dizziness. Emergency assessment is needed if these symptoms occur, especially with kidney problems, dehydration, severe infection, or heavy alcohol intake.
Hypoglycaemia is uncommon with metformin alone. The risk rises when it is combined with insulin or medicines that increase insulin release.
In clinical practice, doctors often start metformin at a tolerable dose and increase it gradually. This approach gives the digestive system time to adapt and can improve continuation of treatment.
A physician will usually judge response through HbA1c rather than a single home glucose reading. HbA1c reflects average glucose exposure over roughly two to three months, while home readings show shorter periods and may vary with meals, illness, stress, sleep, and exercise. These results are interpreted alongside symptoms and treatment adherence. Follow-up frequency depends on clinical risk and the treatment plan.
Metformin is not a rapid symptom-relief tablet. The treatment goal is sustained glucose improvement over time. Some patients notice appetite or digestive changes early, while the full effect on HbA1c requires repeated dosing and follow-up testing.
Diarrhoea is a recognised gastrointestinal side effect of metformin, especially after starting treatment or increasing the dose. Taking Glucophage with food and using gradual dose adjustment can improve tolerance for many patients. Persistent diarrhoea can cause dehydration and may require a temporary treatment review. The FDA's 2017 prescribing information describes gastrointestinal reactions as common during metformin therapy, with reduced symptoms in some patients after continued use [3].
The best timing depends on the prescribed formulation and schedule, though metformin is commonly taken with meals to reduce stomach irritation. A once-daily extended-release schedule is often linked to an evening meal, while other regimens may be divided with meals. The American Diabetes Association’s 2025 treatment principles support individualising administration around glucose patterns, tolerability, kidney function, and the complete diabetes regimen. Taking the tablet at the same meal each day can make missed doses less likely.
Glucophage may be used for many years when it continues to control glucose and remains suitable for the person’s kidney and general health. Type 2 diabetes is usually managed as a long-term condition, so treatment duration is based on HbA1c, glucose readings, kidney tests, weight, side effects, and other clinical findings. NICE guidance published in 2022 supports ongoing review rather than an automatic stopping date for metformin. Vitamin B12 status and kidney function may need periodic assessment during prolonged treatment.
Pregnancy changes glucose targets and treatment decisions, so metformin use should be reviewed individually rather than continued or stopped without clinical direction. The WHO's 2023 guidance identifies diabetes in pregnancy as a condition requiring structured glucose monitoring and maternal-fetal care. Metformin may be used in some pregnancy plans, while insulin may be selected in others depending on the clinical situation. During breastfeeding, the decision considers maternal glucose control, the infant’s health, and the full treatment regimen.
Metformin alone does not usually impair alertness or concentration because it rarely causes hypoglycaemia by itself. Driving risk increases when Glucophage is combined with insulin or insulin-releasing medicines, when meals are skipped, or when illness causes low glucose. The European Medicines Agency's 2016 guidance advises patients to understand the symptoms of hypoglycaemia when metformin is used with treatments that can lower glucose excessively. Dizziness, weakness, confusion, or sweating should be treated as possible low glucose until assessed.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
